HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

AbstractBACKGROUND:
The objective of this study was to assess the antitumor activity and toxicity profile of weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
METHODS:
Patients with recurrent, metastatic, incurable squamous cell carcinoma of the head and neck were enrolled. Weekly docetaxel (30 mg/m2) was administered for 4 weeks every 5 weeks for a maximum of 6 cycles.
RESULTS:
The activity and toxicity of docetaxel were assessed in all 38 patients who were entered on the study. No Grade 3-4 toxicities were recorded. No treatment delays were required because of toxicity or dose reductions. Responses were observed in 42% of patients (95% confidence interval, 26-58%). The median duration of response was 8.39 months, the estimated median overall survival was 11.3 months, and the 1-year survival rate was 39%.
CONCLUSIONS:
The results of this study suggested that weekly docetaxel was an active agent for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
AuthorsRicardo Hitt, Maria L Amador, Miguel Quintela-Fandino, Antonio Jimeno, Olga del Val, Susana Hernando, Hernan Cortes-Funes
JournalCancer (Cancer) Vol. 106 Issue 1 Pg. 106-11 (Jan 01 2006) ISSN: 0008-543X [Print] United States
PMID16329139 (Publication Type: Clinical Trial, Phase II, Journal Article)
CopyrightCopyright 2005 American Cancer Society.
Chemical References
  • Antineoplastic Agents, Phytogenic
  • Taxoids
  • Docetaxel
Topics
  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Agents, Phytogenic (administration & dosage, adverse effects, therapeutic use)
  • Carcinoma, Squamous Cell (drug therapy, mortality, secondary)
  • Docetaxel
  • Drug Administration Schedule
  • Female
  • Head and Neck Neoplasms (drug therapy, mortality, pathology)
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local (drug therapy, mortality)
  • Survival Rate
  • Taxoids (administration & dosage, adverse effects, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: